Annual CFF
$10.52 M
+$6.00 M+132.94%
30 June 2024
Summary:
Renovaro Biosciences annual cash flow from financing activities is currently $10.52 million, with the most recent change of +$6.00 million (+132.94%) on 30 June 2024. During the last 3 years, it has fallen by -$22.08 million (-67.74%). RENB annual CFF is now -67.74% below its all-time high of $32.60 million, reached on 01 June 2021.RENB Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$2.03 M
-$437.50 K-17.74%
30 September 2024
Summary:
Renovaro Biosciences quarterly cash flow from financing activities is currently $2.03 million, with the most recent change of -$437.50 thousand (-17.74%) on 30 September 2024. Over the past year, it has dropped by -$817.70 thousand (-28.72%). RENB quarterly CFF is now -93.05% below its all-time high of $29.20 million, reached on 01 June 2021.RENB Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$9.98 M
-$533.60 K-5.07%
30 September 2024
Summary:
Renovaro Biosciences TTM cash flow from financing activities is currently $9.98 million, with the most recent change of -$533.60 thousand (-5.07%) on 30 September 2024. Over the past year, it has increased by +$1.22 million (+13.89%). RENB TTM CFF is now -71.95% below its all-time high of $35.59 million, reached on 01 December 2021.RENB TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RENB Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +132.9% | -28.7% | +13.9% |
| 3 y3 years | -67.7% | -31.2% | -72.0% |
| 5 y5 years | +74.7% | +100.0% | +87.7% |
RENB Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -67.7% | +147.4% | -31.2% | +776.4% | -72.0% | +306.2% |
| 5 y | 5 years | -67.7% | +147.4% | -93.0% | +776.4% | -72.0% | +306.2% |
| alltime | all time | -67.7% | -93.0% | +776.4% | -72.0% |
Renovaro Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.03 M(-17.7%) | $9.98 M(-5.1%) |
| June 2024 | $10.52 M(+132.9%) | $2.47 M(-6.6%) | $10.52 M(+13.1%) |
| Mar 2024 | - | $2.64 M(-7.2%) | $9.30 M(+6.1%) |
| Dec 2023 | - | $2.85 M(+11.1%) | $8.77 M(+56.0%) |
| Sept 2023 | - | $2.56 M(+105.4%) | $5.62 M(+24.5%) |
| June 2023 | $4.52 M(+6.2%) | - | - |
| June 2023 | - | $1.25 M(-40.8%) | $4.51 M(+4.1%) |
| Mar 2023 | - | $2.11 M(-802.9%) | $4.34 M(+76.4%) |
| Dec 2022 | - | -$300.00 K(-120.6%) | $2.46 M(-56.9%) |
| Sept 2022 | - | $1.46 M(+36.3%) | $5.71 M(+34.3%) |
| June 2022 | $4.25 M(-87.0%) | $1.07 M(+366.3%) | $4.25 M(-86.9%) |
| Mar 2022 | - | $229.50 K(-92.2%) | $32.38 M(-9.0%) |
| Dec 2021 | - | $2.95 M(>+9900.0%) | $35.59 M(+9.2%) |
| Sept 2021 | - | $0.00(-100.0%) | $32.60 M(0.0%) |
| June 2021 | $32.60 M(+352.8%) | $29.20 M(+749.2%) | $32.60 M(+859.3%) |
| Mar 2021 | - | $3.44 M(-8612.4%) | $3.40 M(-44.8%) |
| Dec 2020 | - | -$40.40 K(<-9900.0%) | $6.16 M(-0.7%) |
| Sept 2020 | - | $0.00(0.0%) | $6.20 M(-13.9%) |
| June 2020 | $7.20 M(+19.6%) | $0.00(-100.0%) | $7.20 M(-37.5%) |
| Mar 2020 | - | $6.20 M(>+9900.0%) | $11.52 M(+116.5%) |
| Dec 2019 | - | $0.00(-100.0%) | $5.32 M(-24.2%) |
| Sept 2019 | - | $1.00 M(-76.9%) | $7.02 M(+16.6%) |
| June 2019 | $6.02 M(-64.0%) | $4.32 M(>+9900.0%) | $6.02 M(+254.1%) |
| Mar 2019 | - | $0.00(-100.0%) | $1.70 M(-87.5%) |
| Dec 2018 | - | $1.70 M(>+9900.0%) | $13.60 M(-18.6%) |
| Sept 2018 | - | $0.00(0.0%) | $16.72 M(+0.0%) |
| June 2018 | $16.71 M | $0.00(-100.0%) | $16.71 M(-23.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $11.90 M(+147.1%) | $21.81 M(+119.0%) |
| Dec 2017 | - | $4.82 M(<-9900.0%) | $9.96 M(+93.7%) |
| Sept 2017 | - | -$4500.00(-100.1%) | $5.14 M(-6.6%) |
| June 2017 | $5.51 M(>+9900.0%) | $5.09 M(+9545.6%) | $5.51 M(+1231.1%) |
| Mar 2017 | - | $52.80 K(>+9900.0%) | $413.70 K(+14.6%) |
| Dec 2016 | - | $0.00(-100.0%) | $360.90 K(0.0%) |
| Sept 2016 | - | $360.90 K(>+9900.0%) | $360.90 K(>+9900.0%) |
| June 2016 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2016 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2015 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2015 | - | $0.00(0.0%) | $5.28 M(-9.0%) |
| Mar 2015 | - | $0.00(-100.0%) | $5.80 M(-13.0%) |
| Dec 2014 | $6.67 M(>+9900.0%) | $5.28 M(+896.0%) | $6.67 M(+378.9%) |
| Sept 2014 | - | $530.20 K(-7463.9%) | $1.39 M(+59.7%) |
| June 2014 | - | -$7200.00(-100.8%) | $872.00 K(-0.9%) |
| Mar 2014 | - | $866.00 K(>+9900.0%) | $879.70 K(+3775.3%) |
| Dec 2013 | - | $3700.00(-61.1%) | $22.70 K(-14.3%) |
| Sept 2013 | - | $9500.00(+1800.0%) | $26.50 K(+1.9%) |
| June 2013 | - | $500.00(-94.4%) | $26.00 K(-28.8%) |
| Mar 2013 | $36.50 K(-5.2%) | $9000.00(+20.0%) | $36.50 K(+12.3%) |
| Dec 2012 | - | $7500.00(-16.7%) | $32.50 K(+14.0%) |
| Sept 2012 | - | $9000.00(-18.2%) | $28.50 K(-36.0%) |
| June 2012 | - | $11.00 K(+120.0%) | $44.50 K(+15.6%) |
| Mar 2012 | $38.50 K(+14.9%) | $5000.00(+42.9%) | $38.50 K(+14.9%) |
| Dec 2011 | $33.50 K | $3500.00(-86.0%) | $33.50 K(+11.7%) |
| Sept 2011 | - | $25.00 K(+400.0%) | $30.00 K(+500.0%) |
| June 2011 | - | $5000.00 | $5000.00 |
FAQ
- What is Renovaro Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Renovaro Biosciences?
- What is Renovaro Biosciences annual CFF year-on-year change?
- What is Renovaro Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly CFF year-on-year change?
- What is Renovaro Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Renovaro Biosciences?
- What is Renovaro Biosciences TTM CFF year-on-year change?
What is Renovaro Biosciences annual cash flow from financing activities?
The current annual CFF of RENB is $10.52 M
What is the all time high annual CFF for Renovaro Biosciences?
Renovaro Biosciences all-time high annual cash flow from financing activities is $32.60 M
What is Renovaro Biosciences annual CFF year-on-year change?
Over the past year, RENB annual cash flow from financing activities has changed by +$6.00 M (+132.94%)
What is Renovaro Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of RENB is $2.03 M
What is the all time high quarterly CFF for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly cash flow from financing activities is $29.20 M
What is Renovaro Biosciences quarterly CFF year-on-year change?
Over the past year, RENB quarterly cash flow from financing activities has changed by -$817.70 K (-28.72%)
What is Renovaro Biosciences TTM cash flow from financing activities?
The current TTM CFF of RENB is $9.98 M
What is the all time high TTM CFF for Renovaro Biosciences?
Renovaro Biosciences all-time high TTM cash flow from financing activities is $35.59 M
What is Renovaro Biosciences TTM CFF year-on-year change?
Over the past year, RENB TTM cash flow from financing activities has changed by +$1.22 M (+13.89%)